Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
1(20%)
Results Posted
150%(3 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_3
4
80%

Phase Distribution

1

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(2)

Detailed Status

Terminated2
Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 34 (80.0%)

Trials by Status

terminated240%
active_not_recruiting120%
completed240%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_3

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

NCT05696717
terminatedphase_3

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT03829657
terminatedphase_3

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT04095793
completedphase_3

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT03750552
completedphase_1

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

NCT04200573

Clinical Trials (5)

Showing 5 of 5 trials
NCT05696717Phase 3

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Active Not Recruiting
NCT03829657Phase 3

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Terminated
NCT04095793Phase 3

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Terminated
NCT03750552Phase 3

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Completed
NCT04200573Phase 1

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5